1401466-58-7

Upstream product

• 1401466-52-1 2-(4-bromophenyl)-2-cyclopropylpropionic acid 
• 101-83-7 N-cyclohexyl-cyclohexanamine 
• 1401466-57-6 2-(4-bromo-phenyl)-2-cyclopropyl-1-methoxy-prop-1-yl-hydroperoxide 
• 1401466-54-3 3-(4-bromophenyl)-3-cyclopropyl-1-phenylbutan-1-one 
• 106-37-6 1.4-dibromobenzene 
• 765-43-5 Cyclopropyl methyl ketone 
• 56041-75-9 1-(4-bromophenyl)-1-cyclopropylethan-1-ol 

Downstream Products

• 1360549-37-6 5-(4-{(R)-1-cyclopropyl-1-[5-(1H-pyrazol-4-yl)-[1,2,4]oxadiazol-3-yl]ethyl}phenyl)pyrimidin-2-ylamine 
• 1360550-04-4 2-[4-(3-{(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl}-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl]-N,N-dimethylacetamide 
• 1360551-90-1 (R)-2-(4-bromo-phenyl)-2-cyclopropylpropionitrile 

Relevant academic research and scientific papers

Early Development Scale-Up of a Structurally-Challenging 5-Lipoxygenase Activating Protein (FLAP) Inhibitor

A practical and efficient synthesis of the FLAP inhibitor 1 was developed addressing multiple scale-up and safety concerns posed by the established synthesis and utilized a resolution strategy (replacing supercritical fluid chromatography (SFC) separation) for expedient access to the key structural component of 1: the challenging chiral quaternary center. Also highlighted are in situ IR monitoring, condensation to form the 1,2,4-oxadiazole ring, and an efficient Suzuki-Miyaura coupling.

PROCESS FOR PREPARING CARBOXYLIC ACIDS

The present invention relates to a process of making a compound of formula (XII) or (XIIA): wherein R1,R2, R4 and X are as defined herein.